Tyra BiosciencesTYRA +4.11%28 3-Year ROIIC % is -897.80 as of Dec. 2025. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,325 Biotechnology companies, Tyra Biosciences ranks worse than 93.43% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Tyra Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -897.80%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Tyra Biosciences's 3-Year ROIIC % or its related term are showing as below:
TYRA's 3-Year ROIIC % is ranked worse than 93.43% of 1325
companies
in the Biotechnology industry
Industry Median: -4.44
vs TYRA: -897.80
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tyra Biosciences 3-Year ROIIC % Related Terms
Tyra Biosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYRA vs SION, IOVA, SNDX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Tyra Biosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's 3-Year ROIIC % falls into.
Tyra Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -132.762 (Dec. 2025) - -58.927 (Dec. 2022) )
/
( 17.631 (Dec. 2025) - 9.407 (Dec. 2022) )
=
-73.835
/
8.224
=
-897.80%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tyra Biosciences (TYRA) has a 3-Year ROIIC % of -897.80 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tyra Biosciences and its competitors. According to the industry distribution chart, Tyra Biosciences ranks #1238 out of 1325 companies in the Biotechnology industry, placing it in the top 93.4%.
Is Tyra Biosciences' 3-Year ROIIC % too high?
Tyra Biosciences' current 3-Year ROIIC % is -897.80. Based on the distribution chart, Tyra Biosciences ranks #1238 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' 3-Year ROIIC % compare to SION and IOVA?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #1238 out of 1325 companies for 3-Year ROIIC %. This places Tyra Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tyra Biosciences and its competitors. Tyra Biosciences's current 3-Year ROIIC % is -897.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current 3-Year ROIIC % of -897.80. The current 3-Year ROIIC % is -897.80. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current 3-Year ROIIC % is -897.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score
Get the complete analysis for TYRA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
